JP2015505295A5 - - Google Patents

Download PDF

Info

Publication number
JP2015505295A5
JP2015505295A5 JP2014512088A JP2014512088A JP2015505295A5 JP 2015505295 A5 JP2015505295 A5 JP 2015505295A5 JP 2014512088 A JP2014512088 A JP 2014512088A JP 2014512088 A JP2014512088 A JP 2014512088A JP 2015505295 A5 JP2015505295 A5 JP 2015505295A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
article
container
dosage form
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014512088A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015505295A (ja
JP6072778B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/039219 external-priority patent/WO2012162439A2/en
Publication of JP2015505295A publication Critical patent/JP2015505295A/ja
Publication of JP2015505295A5 publication Critical patent/JP2015505295A5/ja
Application granted granted Critical
Publication of JP6072778B2 publication Critical patent/JP6072778B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014512088A 2011-05-23 2012-05-23 フシジン酸を含む組成物およびそのためのパッケージ Active JP6072778B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161489017P 2011-05-23 2011-05-23
US61/489,017 2011-05-23
PCT/US2012/039219 WO2012162439A2 (en) 2011-05-23 2012-05-23 Compositions comprising fusidic acid and packages therefor

Publications (3)

Publication Number Publication Date
JP2015505295A JP2015505295A (ja) 2015-02-19
JP2015505295A5 true JP2015505295A5 (enExample) 2015-07-16
JP6072778B2 JP6072778B2 (ja) 2017-02-01

Family

ID=47218064

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014512088A Active JP6072778B2 (ja) 2011-05-23 2012-05-23 フシジン酸を含む組成物およびそのためのパッケージ

Country Status (3)

Country Link
US (4) US20140088062A1 (enExample)
JP (1) JP6072778B2 (enExample)
WO (1) WO2012162439A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2772254A3 (en) 2003-03-10 2015-03-11 Optimer Pharmaceuticals, Inc. Novel Antibacterial Agents
JP5698979B2 (ja) 2007-10-25 2015-04-08 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライド系抗菌剤の調製プロセス
EP2358379B1 (en) 2008-10-24 2015-12-16 Cempra Pharmaceuticals, Inc. Biodefenses using triazole-containing macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
EP2475253B1 (en) 2009-09-10 2016-10-26 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and mac diseases
RU2608390C2 (ru) 2010-05-20 2017-01-18 Семпра Фармасьютикалз, Инк. Способы получения макролидов и кетолидов, и промежуточных соединений для их получения
WO2012034058A1 (en) 2010-09-10 2012-03-15 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
JP6208742B2 (ja) 2012-03-27 2017-10-04 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライド抗生物質を投与するための非経口製剤
US9861616B2 (en) 2013-03-14 2018-01-09 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
US9751908B2 (en) 2013-03-15 2017-09-05 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300073A1 (en) * 1987-07-22 1989-01-25 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) Use of fusidic acid in the treatment of aids-related complex and full-blown aids
US6103884A (en) * 1996-03-27 2000-08-15 The University Of Michigan Glycosylated analogs of fusidic acid
JPH11189547A (ja) * 1997-12-26 1999-07-13 Taisho Pharmaceut Co Ltd 安定化されたニコランジル製剤及びその製造方法
JP2005103148A (ja) * 2003-10-01 2005-04-21 Nisshin Kyorin Pharmaceutical Co Ltd ５−アミノサリチル酸の保存方法及び保存システム
EP1736156A4 (en) * 2004-04-15 2010-06-16 Eisai R&D Man Co Ltd COMPOSITION CONTAINING 4-AMINO-5-CHLORO-N-¬ (1R, 3R, 5S) -8-METHYL-8-AZABICYCLO-3.2.1 OCT-3-YL-2-β-methyl-2-ynyloxy BENZAMIDE STABILIZED
WO2006008512A2 (en) * 2004-07-16 2006-01-26 Cipla Limited Anti-histaminic composition
US20060076536A1 (en) * 2004-09-29 2006-04-13 Barshied Scott R Oxygen scavenging pharmaceutical package and methods for making same
EP1977734A1 (en) * 2007-04-03 2008-10-08 Royal College of Surgeons in Ireland A method of producing fast dissolving tablets
CN100566704C (zh) * 2007-10-12 2009-12-09 西藏康欣药业有限公司 夫西地酸钠冻干粉针剂
CN102065893A (zh) * 2008-04-15 2011-05-18 萨可德公司 Lfa-1拮抗剂向胃肠系统的递送
WO2010095091A1 (en) * 2009-02-18 2010-08-26 Sulur Subramaniam Vanangamudi A process to make fusidic acid cream
US20120035144A1 (en) * 2009-04-20 2012-02-09 Apex Laboratories Private Limited Medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid, and an antifungal agent, and a process to make it.
US8450300B2 (en) * 2009-07-13 2013-05-28 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections

Similar Documents

Publication Publication Date Title
JP2015505295A5 (enExample)
JP2010132695A5 (enExample)
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
JP2015078230A5 (enExample)
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
JP2010222367A5 (enExample)
EA201291410A1 (ru) Фармацевтические композиции, содержащие 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1h-бензимидазол-2-ил]-1h-хинолин-2-она лактат моногидрат
JP2016510019A5 (enExample)
JP2012236834A5 (enExample)
JP2010520246A5 (enExample)
JP2014530801A5 (enExample)
JP2013518051A5 (enExample)
CA2692191C (en) Use of conjugates of hyaluronic acid in the local treatment of hyperproliferative skin diseases
ECSP13012399A (es) Un nuevo conjugado de granulocito colonia-estimulante factor (g-csf) con polietileno
JP2012508256A5 (enExample)
HK1203050A1 (en) Novel dosage and formulation
TN2014000031A1 (en) Use of organic compound for the treatment of noonan syndrome
JP2014510156A5 (enExample)
WO2011093815A3 (en) Pharmaceutical compositions comprising formoterol and mometasone
WO2011093818A3 (en) Pharmaceutical compositions comprising salmeterol and fluticasone
JP2016537364A5 (enExample)
JP2016538288A5 (enExample)
JP2015521647A5 (enExample)
JP2016540799A5 (enExample)
WO2011093811A3 (en) Pharmaceutical preparations comprising formoterol and fluticasone